What is the projected growth of the global IVD contract manufacturing market?

The global market was valued at USD 19.81 billion in 2024 and is expected to grow to USD 45.50 billion by 2032, registering a compound annual growth rate of 11.12% over the forecast period 2025 to 2032.

Which factors are driving the adoption of IVD contract manufacturing services?

Key drivers include the rising demand for high-precision diagnostic solutions and the increasing complexity of modern assays. Healthcare providers, laboratories, and research institutions are seeking reliable, scalable, and regulatory-compliant production services. Advancements in automation, integrated service offerings, and assay development technologies further enhance efficiency and reduce time-to-market.

What are the major challenges limiting the growth of the market?

Intellectual property protection is a major challenge in IVD contract manufacturing, as outsourcing exposes proprietary assays and technologies to misuse. Ensuring security requires strong legal agreements, strict confidentiality, and careful partner selection. Companies address these risks through secure production processes and advanced data protection systems.

Which technological trends are shaping the IVD contract manufacturing industry?

Automation and digital technologies are driving higher throughput, improved accuracy, and streamlined regulatory compliance in IVD contract manufacturing. Smart facilities and integrated quality management platforms enable scalable production of complex diagnostics. Adoption of AI-driven workflows enhances efficiency, reduces costs, and ensures consistent product quality.

Which regions are leading in IVD contract manufacturing adoption, and why?

North America leads the market with a 36.47% share in 2024, driven by strong healthcare infrastructure, advanced molecular and point-of-care diagnostics, and significant investments in R&D and automation. Asia Pacific is the fastest-growing region, projected to expand at a CAGR of 12.34%, supported by rising demand for advanced diagnostics, expanding contract manufacturing capabilities, and supportive government policies. Both regions benefit from strategic collaborations between local and global diagnostic companies and continuous advancements in production automation.

What are the most in-demand service types and product segments in IVD contract manufacturing?

The most in-demand service is manufacturing services, which earned USD 12.82 billion in 2024 due to large-scale outsourcing by IVD companies. Reagents lead the product segments with a 42.56% market share, driven by their essential role in molecular diagnostics, immunoassays, and routine laboratory testing. Research and development services and packaging services are also growing, supporting complex assay production and regulatory compliance needs.

How are regulatory frameworks impacting IVD contract manufacturing globally?

Regulatory compliance is critical for ensuring safe and effective diagnostics. In the U.S., 21 CFR Part 809 sets requirements for labeling, performance standards, and premarket approval, while the EU’s Regulation (EU) 2017/746 governs risk classification, conformity assessment, and post-market surveillance. Contract manufacturers must adhere to these standards to maintain quality and legal compliance.

How can this report help me explain the benefits of outsourcing IVD manufacturing services to my clients?

This report highlights the advantages of partnering with specialized IVD contract manufacturers, including access to advanced technologies, regulatory expertise, and scalable production. It shows how outsourcing accelerates product launches, reduces costs, and ensures compliance with global standards. You can use these insights to demonstrate to clients how reliable, high-precision diagnostic solutions can be delivered efficiently.

How does this report help me understand the competitive landscape and identify potential partners in IVD contract manufacturing?

The report provides a detailed overview of major global players, their service offerings, and strategic initiatives, giving a clear picture of the competitive landscape. It highlights trends such as automation, high-throughput production, and integrated service solutions that shape market dynamics. You can use this information to identify potential partners or benchmark your strategy against competitors. Regional insights and recent collaborations help evaluate opportunities for effective partnerships.

How can I use this report to assess market growth and quantify investment opportunities in the IVD contract manufacturing sector?

This report includes market sizing, segmentation, and CAGR projections across services, products, and regions, enabling accurate assessment of growth potential. It identifies high-growth areas such as reagents, research institutes, and the Asia Pacific region. Analysis of market drivers, technological trends, and regulatory milestones helps quantify opportunities and risks. You can leverage these insights to inform investment strategies and identify profitable areas for expansion.

How does this report help me understand the key challenges and risks in IVD contract manufacturing?

The report highlights major challenges such as intellectual property protection risks, regulatory compliance, and operational complexities across multiple manufacturing sites. It explains how companies mitigate these risks through secure production processes, confidentiality protocols, and advanced data protection systems. You can use these insights to evaluate potential partners and implement safeguards in your own outsourcing strategy. Understanding these risks helps ensure consistent product quality and protects competitive advantage.

IVD Contract Manufacturing Market Research Report [2032]

Q: Who are the key players operating in the global market?

Key players in market are Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Jabil Inc., Flex Medical Solutions Ltd, Celestica Inc., Sanmina Corporation, Benchmark Electronics, Inc., Invetech, Meridian Bioscience, Inc., Avioq, Inc., TCS Biosciences, Savyon Diagnostics, BD, and Cenogenics Corporation.

Market Definition

In-vitro diagnostics (IVD) contract manufacturing involves outsourcing the design, development, and production of diagnostic devices, reagents, and consumables to specialized manufacturers. It enables companies to leverage advanced technologies, regulatory expertise, and scalable manufacturing capabilities.

This service supports the manufacturing of molecular diagnostics, immunoassays, clinical chemistry, and point-of-care testing products. Its importance is growing as diagnostic providers focus on reducing costs, accelerating product launches, and meeting stringent quality and compliance standards worldwide.

IVD Contract Manufacturing Market Overview

According to Kings Research, the global IVD contract manufacturing market size was valued at USD 19.81 billion in 2024 and is projected to grow from USD 21.75 billion in 2025 to USD 45.50 billion by 2032, exhibiting a CAGR of 11.12% during the forecast period.

This growth is driven by the increasing complexity of diagnostic technologies and a shift toward cost-effective outsourcing models among in-vitro diagnostics manufacturers. Rising demand for molecular diagnostics, immunoassays, and point-of-care testing solutions is fueling adoption across healthcare and research applications.

Key Market Highlights:

The IVD contract manufacturing industry size was USD 19.81 billion in 2024.
The market is projected to grow at a CAGR of 11.12% from 2025 to 2032.
North America held a share of 36.47% in 2024, valued at USD 7.22 billion.
The manufacturing services segment garnered USD 12.82 billion in revenue in 2024.
The reagents segment is expected to reach USD 18.20 billion by 2032.
The research & academic institutes segment is anticipated to witness the fastest CAGR of 11.81% over the forecast period.
Asia Pacific is anticipated to grow at a CAGR of 12.34% through the projection period.

Major companies operating in the IVD contract manufacturing market are Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Jabil Inc., Flex Medical Solutions Ltd, Celestica Inc., Sanmina Corporation, Benchmark Electronics, Inc., Invetech, Meridian Bioscience, Inc., Avioq, Inc., TCS Biosciences, Savyon Diagnostics, BD, and Cenogenics Corporation.

Surging emphasis on regulatory compliance, quality assurance, and scalable production is supporting broader engagement of contract manufacturing partners. Additionally, advancements in automation, strategic collaborations, and integrated service offerings are propelling continued market expansion.

In July 2025, ClearNote Health received UK Conformity Assessed (UKCA) marking for its Avantect pancreatic cancer in-vitro diagnostic test. The approval enables its commercial launch in the UK and marks the company’s transition from laboratory-developed assays to regulated diagnostics. The Avantect test analyzes circulating cell-free DNA using epigenomic and genomic sequencing, supporting global expansion and enhancing early pancreatic cancer detection.

How is growing demand for precise diagnostic solutions driving market growth?

The IVD contract manufacturing market is witnessing significant growth, mainly due to growing demand for precise diagnostic solutions and the rising complexity of modern assays.

Laboratories, healthcare providers, and research institutions increasingly require scalable, reliable, and regulatory-compliant production services for molecular diagnostics, immunoassays, and point-of-care tests.

For instance, in March 2024, the FDA granted 510(k) clearance for Luminex Molecular Diagnostics’ NxTAG Respiratory Pathogen Panel v2, a next-generation sequencing assay that identifies multiple respiratory pathogens in a single test, highlighting the need for advanced manufacturing capabilities.

Moreover, diagnostic companies are increasingly partnering with contract manufacturers to accelerate product development, reduce costs, and ensure regulatory compliance. Continued advancements in automation, assay development technologies, and integrated service offerings are further supporting sustained market growth.

How are intellectual property risks influencing the IVD contract manufacturing market?

Intellectual property protection risks pose a significant challenge to the progress of the market. Outsourcing production exposes sensitive assays, formulations, and technologies to potential misuse or unauthorized access, creating risks for diagnostic companies.

These risks can result in competitive disadvantages, financial losses, and damage to trust between clients and manufacturers, particularly for smaller or emerging firms.

Ensuring secure handling of intellectual property requires robust legal agreements, strict confidentiality protocols, and careful selection of manufacturing partners. However, limited oversight and enforcement across multiple sites increase exposure to potential breaches.

To mitigate these risks, companies are increasingly investing in secure production processes, advanced data protection systems, and stringent contractual safeguards. These measures aim to strengthen IP security, maintain competitive advantage, and support long-term growth in the contract manufacturing sector.

How is the integration of advanced automation and digital technologies transforming this market?

The in‑vitro diagnostics contract manufacturing market is experiencing a notable trend toward the adoption of automation and digital technologies, along with increasing demand for precise, scalable diagnostic solutions across healthcare, research, and point-of-care settings.

Automated production systems and digital quality management platforms are being optimized for higher throughput, enhanced accuracy, and streamlined regulatory compliance, while smart manufacturing facilities are being designed to handle increasing volumes of complex diagnostic products.

This shift has accelerated as diagnostic companies aim to reduce time-to-market, improve operational efficiency, and ensure product consistency. Contract manufacturers, technology providers, and research institutions are investing in automated workflows, high-throughput platforms, and integrated digital solutions to scale production capabilities.

Continuous adoption of automation and digital technologies is expected to boost productivity, reduce costs, and foster significant market growth over the forecast period.

In May 2025, Tempus received U.S. FDA 510(k) clearance for its RNA-based Tempus xR in‑vitro diagnostic device, a next-generation sequencing assay for detecting gene rearrangements in solid tumors. The device analyzed RNA from formalin-fixed paraffin-embedded tumor samples and supported oncology drug development by identifying gene fusions and molecular pathways. This clearance highlighted Tempus’ focus on advancing precision medicine through AI-driven diagnostics and integrated data solutions.

IVD Contract Manufacturing Market Report Snapshot

Segmentation	Details
By Service Type	Manufacturing Services, Research & Development (R&D) Services, and Packaging Services
By Product Type	Reagents, Diagnostic Devices & Instruments, Assay Kits, and Consumables
By End User	Pharmaceutical & Biotechnology Companies, Hospitals & Clinical Laboratories, and Research & Academic Institutes
By Region	North America: U.S., Canada, Mexico
	Europe: France, UK, Spain, Germany, Italy, Russia, Rest of Europe
	Asia-Pacific: China, Japan, India, Australia, ASEAN, South Korea, Rest of Asia-Pacific
	Middle East & Africa: Turkey, U.A.E., Saudi Arabia, South Africa, Rest of Middle East & Africa
	South America: Brazil, Argentina, Rest of South America

Market Segmentation

By Service Type (Manufacturing Services, Research & Development (R&D) Services, and Packaging Services): The manufacturing services segment earned USD 12.82 billion in 2024, primarily due to increasing demand for high-precision diagnostic production and large-scale outsourcing by IVD companies.
By Product Type (Reagents, Diagnostic Devices & Instruments, Assay Kits, and Consumables): The reagents segment held a share of 42.56% in 2024, propelled by their essential role in molecular diagnostics, immunoassays, and routine laboratory testing.
By End User (Pharmaceutical & Biotechnology Companies, Hospitals & Clinical Laboratories, and Research & Academic Institutes): The pharmaceutical & biotechnology companies segment is projected to reach USD 22.03 billion by 2032, owing to increasing outsourcing of diagnostic production and growing demand for advanced assays and personalized medicine solutions.

What is the market scenario in North America and Asia-Pacific region?

Based on region, the global market has been classified into North America, Europe, Asia Pacific, Middle East & Africa, and South America.

IVD Contract Manufacturing Market Size & Share, By Region, 2025-2032

North America IVD contract manufacturing market share stood at 36.47% in 2024, valued at USD 7.22 billion. Strong healthcare infrastructure, the presence of leading diagnostic companies, and high adoption of advanced molecular and point-of-care diagnostics are further boosting this expansion.

The regional market further benefits from significant investments in research and development, automation, and quality management systems, which are enhancing manufacturing efficiency and scalability. Strategic collaborations between domestic and global players, along with supportive regulatory frameworks, further strengthen growth prospects.

Continuous advancements in assay technologies, production automation, and integrated digital solutions position North America as a key hub for IVD contract manufacturing.

In April 2025, Roche invested USD 50 billion in the U.S. over five years to expand its pharmaceutical and diagnostics operations. The plan included new and upgraded manufacturing sites in Indiana, Pennsylvania, Massachusetts, and California, along with an R&D center in Massachusetts dedicated to AI-driven research in cardiovascular, renal, and metabolic disease.

Asia Pacific IVD contract manufacturing market is set to grow at a CAGR of 12.34% over the forecast period. This growth is fueled by rising demand for advanced diagnostic solutions, increasing outsourcing of production, and the expansion of contract manufacturing capabilities.

The regional sector further benefits from supportive government policies, investments in healthcare infrastructure, and collaborations between local and international diagnostic companies.

The presence of a large patient population and growing adoption of molecular and point-of-care diagnostics are creating strong opportunities for high-precision assay production. Additionally, advancements in automation, digital quality management, and high-throughput manufacturing are fostering innovation, aiding regional market expansion.

Regulatory Frameworks

In the U.S., 21 CFR Part 809 regulates in‑vitro diagnostic devices. It establishes requirements for labeling, performance standards, and premarket approval or clearance, ensuring that IVD contract manufacturers produce safe and effective diagnostic products compliant with FDA standards.
In the EU, Regulation (EU) 2017/746 governs in‑vitro diagnostic devices. It establishes requirements for risk classification, conformity assessment, clinical evidence, and post-market surveillance, ensuring that IVD products meet safety, performance, and quality standards throughout their lifecycle.

Competitive Landscape

Companies operating in the in‑vitro diagnostics contract manufacturing market are maintaining competitiveness through investments in advanced automation, high-throughput production systems, and digital quality management platforms.

They are focusing on expanding manufacturing capacity and enhancing operational efficiency to meet growing demand for molecular diagnostics, immunoassays, and point-of-care testing solutions.

Key players are broadening their service portfolios to include assay development, regulatory support, packaging, and integrated end-to-end manufacturing, supported by strategic partnerships, mergers, and collaborations with diagnostic developers.

In January 2025, Revvity and Element Biosciences collaborated to develop an in‑vitro diagnostic (IVD) workflow for neonatal sequencing. The partnership integrated Revvity’s automated newborn sequencing technology with Element’s AVITI system to deliver a comprehensive end-to-end solution for newborn screening. A research-use-only (RUO) version was launched, with regulatory approval for clinical use planned.

Firms are increasingly focusing on forming collaborations with healthcare providers, research institutions, and technology vendors to expedite product development and minimize commercialization timelines. Additionally, companies are enhancing technical expertise, implementing digital monitoring systems, and leveraging automation and smart manufacturing solutions to sustain a competitive advantage.

List of Key Companies in IVD Contract Manufacturing Market:

Thermo Fisher Scientific Inc.
Merck KGaA
Danaher Corporation
Jabil Inc.
Flex Medical Solutions Ltd
Celestica Inc.
Sanmina Corporation
Benchmark Electronics, Inc.
Invetech
Meridian Bioscience, Inc.
Avioq, Inc.
TCS Biosciences
Savyon Diagnostics
BD
Cenogenics Corporation

Recent Developments

In January 2025, Akoya Biosciences appointed Argonaut Manufacturing Services as its manufacturing partner for developing in vitro diagnostic (IVD) assays. The collaboration builds on their existing partnership, leveraging Argonaut’s cGMP and ISO 13485-certified capabilities to support diagnostic product scale-up and commercialization in regulated markets.